The role of targeted therapy for gastrointestinal tumors

被引：29
作者：
Rolfo, Christian [1 ]
Bronte, Giuseppe [2 ]
Sortino, Giovanni [2 ]
Papadimitriou, Konstantinos [1 ]
Passiglia, Francesco [1 ,2 ]
Fiorentino, Eugenio [2 ]
Marogy, Ghada [1 ]
Russo, Antonio [2 ]
Peeters, Marc [1 ]
机构：
[1] Univ Antwerp, Univ Hosp Antwerp UZA, Dept Oncol, B-2650 Antwerp, Belgium
[2] Univ Palermo, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy
来源：
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2014年 / 8卷 / 08期
关键词：
colorectal cancer; gastric cancer; gastrointestinal tumors; hepatocellular carcinoma; neuroendocrine tumors; targeted therapy; METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; ADVANCED GASTRIC-CANCER; PHASE-II TRIAL; ADVANCED HEPATOCELLULAR-CARCINOMA; GASTROESOPHAGEAL JUNCTION; 1ST-LINE TREATMENT; RANDOMIZED PHASE-3; NEUROENDOCRINE TUMORS; 2ND-LINE TREATMENT;
D O I：
10.1586/17474124.2014.922870
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
引用
收藏
页码：875 / 885
页数：11
相关论文
共 93 条
[1]   Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC) [J].
Abou-Alfa, G. K. ;
Gansukh, B. ;
Chou, J. F. ;
Shia, J. ;
Capanu, M. ;
Kalin, M. ;
Chen, H. X. ;
Zojwalla, N. J. ;
Katz, S. ;
Reidy, D. L. ;
Kelsen, D. P. ;
Saltz, L. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2]   A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer [J].
Altomare, Ivy ;
Bendell, Johanna C. ;
Bullock, Karen E. ;
Uronis, Hope E. ;
Morse, Michael A. ;
Hsu, S. David ;
Zafar, S. Yousuf ;
Blobe, Gerard C. ;
Pang, Herbert ;
Honeycutt, Wanda ;
Sutton, Linda ;
Hurwitz, Herbert I. .
ONCOLOGIST, 2011, 16 (08) :1131-1137
[3]  
[Anonymous], NCT01662869
[4]  
[Anonymous], NCT01697072
[5]  
Bang YJ, 2010, LANCET, V376, P1302
[6]  
Bang Y-J, 2012, J CLIN ONCOL S34, V30
[7]   Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer [J].
Barok, Mark ;
Tanner, Minna ;
Koninki, Katri ;
Isola, Jorma .
CANCER LETTERS, 2011, 306 (02) :171-179
[8]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[9]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[10]  
Bronte Giuseppe, 2011, Front Biosci (Elite Ed), V3, P879
12345678910